Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Stefan Aebi, T. Davidson, Günther Gruber et al. · Annals of Oncology · 2010 · 2.9K citations · Full text

Medicine, Oncology, Surgery +14

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

Medicine, Oncology, Breast Oncology +6

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fátima Cardoso, S. Kyriakides, Shinji Ohno et al. · Annals of Oncology · 2019 · 2.2K citations · Full text

Medicine, Oncology, Breast Oncology +13

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Medicine, Endocrinology, Oncology +14

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13